$CATX Cashflow Statement | Understand Stock

$CATX

$1.25 +$0.06 (5.04%) Close

$CATX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2021 12 months to Jun 30, 2022	FY2020 12 months to Jun 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Lease expense
Depreciation expense
Write-off of inventory associated with discontinued product
Foreign currency adjustments
Depreciation expense and amortization
Loss on disposal of property and equipment
Amortization of other assets
Accretion of asset retirement obligation
Equity in loss of affiliate
Accrued interest on short-term investments
Change in allowance for doubtful accounts
Change in estimate of asset retirement obligation
Net accretion of discounts on available-for-sale securities
Loss on divestiture
Goodwill impairment
In-process research and development impairment
Share-based compensation
Deferred income tax benefit
Other, net
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Inventory related to discontinued operations (Note 4)
Interest receivable
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued protocol expense
Accrued radioactive waste disposal
Accrued payroll and related taxes
Accrued vacation
Deferred Income
Accrued personnel expenses
Other noncurrent liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment
Additions to equity method investment
Proceeds from maturity of short-term investments
Proceeds from the sale of property and equipment
Additions to other assets
Maturities of available-for-sale securities
Purchases of available-for-sale securities
Proceeds from maturity of held-to-maturity investments
Purchases of held-to-maturity investments
Investment in note receivable
Net cash acquired in acquisition of Viewpoint
Net cash provided by (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid
Repayment of notes payable
Proceeds from sales of common stock, pursuant to exercise of warrants, net
Proceeds from sales of common stock, pursuant to exercise of options
Proceeds from the issuance of Pre-funded Warrants, net
Issuance costs related to common stock issued in exchange for Viewpoint common stock
Proceeds from the sales of common stock and Pre-funded Warrants, net
Proceeds from the issuance of common stock pursuant to the ATM, net
Net cash provided by financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
CASH AND CASH EQUIVALENTS AT END OF PERIOD
Interest paid
Cash and cash equivalents
Restricted cash
Supplemental schedule of noncash investing and financing activities:
Property and equipment in accounts payable and accrued expenses
Recognition of operating lease liability and right-of-use asset
Modification of operating lease liability and right-of-use asset
Operating lease liability and right of use asset for new lease
Fair value of Viewpoint assets acquired including goodwill
13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock
Assumption of Viewpoint stock options and warrants at fair value
Note receivable and accrued interest from Viewpoint forgiven
Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (see Note 14)

Comments